Angiotensin Converting Enzyme Inhibitors and Periprocedural Myocardial Infarction

Angiotensin Converting Enzyme Inhibitor Therapy and Periprocedural Myocardial Infarction in Patients With Metabolic Syndrome

Metabolic syndrome (MS) has been reported as a risk for cardiovascular events. The aim of the present cohort study is to investigate whether ACEi therapy reduces the rate of periprocedural myocardial injury (PPMI) after elective percutaneous coronary intervention (PCI) among patients with metabolic syndrome.

Study Overview

• Status: Completed
• Conditions: Coronary Artery Disease; Metabolic Syndrome

• Study Type: Observational
• Enrollment (Actual): 459

Contacts and Locations

Study Locations

• Turkey
  • Ankara, Turkey, 06230
    • Ankara University School Of Medicine, Department of Cardiology

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Metabolic syndorme (MS) was defined as the presence of 3 or more of these components:

1. high fasting glucose (fasting serum glucose ≥100 mg/dl or drug treatment for elevated blood glucose)
2. abdominal obesity (given as waist circumference >102 cm in men and >88 cm in women)
3. high blood pressure (>130/>85 mmHg or drug treatment for hypertension)
4. hypertriglyceridemia (serum triglycerides ≥150 mg/dl)
5. low high-density lipoprotein (HDL) cholesterol (<40 mg/dl in men and <50 mg/dl in women).

Description

Inclusion Criteria:

1. metabolic syndrome
2. elective percutaneous coronary intervention with angiographically successful stent implantation

Exclusion Criteria:

1. acute coronary events
2. renal failure
3. needed the use of IV glycoprotein IIb/IIIa receptor inhibitors were excluded
4. left main coronary artery disease
5. chronic total occlusion
6. high levels of baseline CKMB or troponin
7. any contraindication of aspirin, clopidogrel or ACEi treatment

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Periprocedural myocardial injury (MI)	Periprocedural MI was defined as cardiac Troponin I release [5 times ULN] 24 hours after percutaneous coronary intervention	24 hours after (percutaneous coroary intervention) PCI

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Periprocedural myonecrosis	Peri-procedural myonecrosis was defined as troponin I release of >1×ULN 24 hours after the intervention.	24 hours after PCI

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
inflammatory marker	high sensitive C-reactive protein measurement 24 hours after PCI	24 hours after PCI

Collaborators and Investigators

• Sponsor: Ankara University

Study record dates

Study Major Dates

• Study Start: February 1, 2014
• Primary Completion (Actual): June 1, 2014
• Study Completion (Actual): June 1, 2014

Study Registration Dates

• First Submitted: February 3, 2014
• First Submitted That Met QC Criteria: February 3, 2014
• First Posted (Estimate): February 4, 2014

Study Record Updates

• Last Update Posted (Estimate): June 20, 2014
• Last Update Submitted That Met QC Criteria: June 19, 2014
• Last Verified: June 1, 2014

More Information

Terms related to this study

• Keywords: percutaneous coronary intervention; inflammation; metabolic syndrome; Angiotensin converting enzyme inhibitor; periprocedural myocardial injury; myonecrosis
• Additional Relevant MeSH Terms: Ischemia; Pathologic Processes; Necrosis; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Glucose Metabolism Disorders; Metabolic Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Disease; Insulin Resistance; Hyperinsulinism; Coronary Disease; Myocardial Infarction; Infarction; Coronary Artery Disease; Syndrome; Metabolic Syndrome
• Other Study ID Numbers: ACEmetsend